Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Morrow

Showing results (471-480 of 942) with videos related to

Pageof 95
Sort By:
Journal of the American Heart Association|April 12, 2021
Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36Thomas A Zelniker, David A Morrow, Benjamin M Scirica, et al.
European Journal of Preventive Cardiology|February 24, 2021
Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndromeBaris Gencer, David A Morrow, Eugene Braunwald, et al.
Diabetes|February 1, 1994
Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistanceD E Moller, O Cohen, Y Yamaguchi, et al.
Journal of the American Heart Association|October 30, 2018
Cystatin C for Risk Stratification in Patients After an Acute Coronary SyndromeSimon Correa, David A Morrow, Eugene Braunwald, et al.
Clinical Cardiology|June 11, 2015
Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 TrialJorge A Gutierrez, Ewa Karwatowska-Prokopczuk, Sabina A Murphy, et al.
Journal of Critical Care|August 24, 2018
Progressive myocardial injury is associated with mortality in the acute respiratory distress syndromeThomas S Metkus, Eliseo Guallar, Lori Sokoll, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Periventricular gradients in axonal and myelin microstructure are present in people with multiple sclerosis having low and high disabilityHannah R Bernstein, Vladimir Grouza, Joseph S Gati, et al.
European Heart Journal|May 17, 2019
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trialDavid A Morrow, Eric J Velazquez, Adam D DeVore, et al.
European Heart Journal|April 20, 2010
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trialDavid A Morrow, Elliott M Antman, Keith A A Fox, et al.
Journal of the American College of Cardiology|November 27, 2007
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trialJames A de Lemos, David A Morrow, Michael A Blazing, et al.
Pageof 95

Showing results (471-480 of 942) with videos related to

Sort By:
Pageof 95
Journal of the American Heart Association|April 12, 2021
Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36Thomas A Zelniker, David A Morrow, Benjamin M Scirica, et al.
European Journal of Preventive Cardiology|February 24, 2021
Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndromeBaris Gencer, David A Morrow, Eugene Braunwald, et al.
Diabetes|February 1, 1994
Prevalence of mutations in the insulin receptor gene in subjects with features of the type A syndrome of insulin resistanceD E Moller, O Cohen, Y Yamaguchi, et al.
Journal of the American Heart Association|October 30, 2018
Cystatin C for Risk Stratification in Patients After an Acute Coronary SyndromeSimon Correa, David A Morrow, Eugene Braunwald, et al.
Clinical Cardiology|June 11, 2015
Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 TrialJorge A Gutierrez, Ewa Karwatowska-Prokopczuk, Sabina A Murphy, et al.
Journal of Critical Care|August 24, 2018
Progressive myocardial injury is associated with mortality in the acute respiratory distress syndromeThomas S Metkus, Eliseo Guallar, Lori Sokoll, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 27, 2025
Periventricular gradients in axonal and myelin microstructure are present in people with multiple sclerosis having low and high disabilityHannah R Bernstein, Vladimir Grouza, Joseph S Gati, et al.
European Heart Journal|May 17, 2019
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trialDavid A Morrow, Eric J Velazquez, Adam D DeVore, et al.
European Heart Journal|April 20, 2010
One-year outcomes after a strategy using enoxaparin vs. unfractionated heparin in patients undergoing fibrinolysis for ST-segment elevation myocardial infarction: 1-year results of the ExTRACT-TIMI 25 trialDavid A Morrow, Elliott M Antman, Keith A A Fox, et al.
Journal of the American College of Cardiology|November 27, 2007
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trialJames A de Lemos, David A Morrow, Michael A Blazing, et al.
Pageof 95